Demo Data from EDBT 2026 / reviewers in the wild / expert
Lixia Diao
dblp:132/3508
· DBLP profile ↗
4ranked-venue papers
0as first author
1since 2021 · last 2021
0000-0001-6995-4492ORCID · corroborated
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 4 · 1 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
2 papers |
Bioinformatics and computational biology · 64% Medical and health informatics · 36% |
Topics — the 3 heaviest of 3, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Medical and health informatics
dose-response modeling |
0.2 | 1 | 2015 | drexplorer: A tool to explore dose-response relationships and drug-drug interactions · Bioinform. 2015 |
Bioinformatics and computational biology › clinical bioinformatics
drug response analysis |
0.2 | 1 | 2015 | drexplorer: A tool to explore dose-response relationships and drug-drug interactions · Bioinform. 2015 |
Bioinformatics and computational biology › transcriptomics
cancer transcriptomics |
0.2 | 1 | 2013 | DeMix: deconvolution for mixed cancer transcriptomes using raw measured data · Bioinform. 2013 |
Methods — techniques the papers use, named apart from their topics
nonlinear dose-response modeling · 0.2IC50 estimation · 0.2statistical deconvolution · 0.2
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2021 | Adverse events associated with potential drugs for COVID-19: a case study from real-world dataabstractThe coronavirus disease 2019 (COVID-19) has resulted as a global pandemic. The World Health Organization announced the most promising drugs in SOLIDARITY for the global trial, and several other drugs are under investigation through ongoing clinical trials to prove the effectiveness and safety of potential therapeutics. Here, we depicted the safety profile of these drugs and investigated their associated adverse events (AEs). We observed the associated AEs in different organs/systems, especially in skin and subcutaneous tissue, immune system and musculoskeletal and connective tissue. Furthermore, we observed strong bias of AEs in different groups of sex and age. Our study provides knowledge of the toxicity of potential COVID-19 drugs. While these drugs hold promise to fight the global pandemic, healthcare providers should pay attention to AEs to maximize the treatment benefit while minimizing toxicity. Lixia Diao, Leng Han |
Briefings Bioinform. | 2 |
| 2019 | CircView: a visualization and exploration tool for circular RNAsabstractCircular RNAs (circRNAs) are novel rising stars of noncoding RNAs, which are highly abundant and evolutionarily conserved across species. Number of publications related to circRNAs increased sharply in recent years, representing emerging focuses in the field. Therefore, tools, pipelines and databases have been developed to identify and store circRNAs. However, there is no existing tool to visualize and explore circRNAs. Therefore, we introduce CircView, a user-friendly visualization tool for circRNAs detected from existing tools. CircView enables users to visualize circRNAs and to quantify number of samples with detected circRNAs. CircView allows users to explore circRNAs detected by unique or multiple tools. Furthermore, CircView allows users to view the regulatory elements, such as microRNA response elements and RNA-binding protein binding sites. CircView is a unique tool to visualize and explore circRNAs, which helps users to better understand potential functions of circRNAs and design the functional experiments. Jing Feng 0005, Si-Yu Xia, Jun Wang 0154, Fatma Muge Ozguc, Lijun Lei, Ruoshan Kong, Lixia Diao, Chunjiang He, Leng Han |
Briefings Bioinform. | 9 |
| 2015 | drexplorer: A tool to explore dose-response relationships and drug-drug interactionsabstractAbstract Motivation: Nonlinear dose–response models are primary tools for estimating the potency [e.g. half-maximum inhibitory concentration (IC) known as IC50] of anti-cancer drugs. We present drexplorer software, which enables biologists to evaluate replicate reproducibility, detect outlier data points, fit different models, select the best model, estimate IC values at different percentiles and assess drug–drug interactions. drexplorer serves as a computation engine within the R environment and a graphical interface for users who do not have programming backgrounds. Availability and implementation: The drexplorer R package is freely available from GitHub at https://github.com/nickytong/drexplorer. A graphical user interface is shipped with the package. Contact: [email protected] Supplementary information: Supplementary data are available at Bioinformatics online. Pan Tong, Kevin R. Coombes, Faye M. Johnson, Lauren A. Byers, Lixia Diao, Diane D. Liu, J. Jack Lee, John V. Heymach, Jing Wang 0006 |
Bioinform. | 5 |
| 2013 | DeMix: deconvolution for mixed cancer transcriptomes using raw measured dataabstractMOTIVATION: Tissue samples of tumor cells mixed with stromal cells cause underdetection of gene expression signatures associated with cancer prognosis or response to treatment. In silico dissection of mixed cell samples is essential for analyzing expression data generated in cancer studies. Currently, a systematic approach is lacking to address three challenges in computational deconvolution: (i) violation of linear addition of expression levels from multiple tissues when log-transformed microarray data are used; (ii) estimation of both tumor proportion and tumor-specific expression, when neither is known a priori; and (iii) estimation of expression profiles for individual patients. RESULTS: We have developed a statistical method for deconvolving mixed cancer transcriptomes, DeMix, which addresses the aforementioned issues in array-based expression data. We demonstrate the performance of our model in synthetic and real, publicly available, datasets. DeMix can be applied to ongoing biomarker-based clinical studies and to the vast expression datasets previously generated from mixed tumor and stromal cell samples. AVAILABILITY: All codes are written in C and integrated into an R function, which is available at http://odin.mdacc.tmc.edu/∼wwang7/DeMix.html. CONTACT: [email protected] SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Jaeil Ahn, Giovanni Parmigiani, Milind B. Suraokar, Lixia Diao, Ignacio I. Wistuba, Wenyi Wang 0001 |
Bioinform. | 5 |